Agenus buys a Xoma plant; Alzheon moves toward Phase III with Alzheimer's drug;

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> Agenus ($AGEN) is acquiring a biologics manufacturing plant from Xoma ($XOMA) for $5 million. More

> Startup Alzheon has launched a pair of clinical trials to prepare its Alzheimer's disease candidate for Phase III development. The company raised $10 million to support the project earlier this year. News

> Cellectis ($CLLS), developing an off-the-shelf version of CAR-T technology, said it's therapy for hard-to-treat leukemia posted positive results in an early-stage study. Item

Medical Device News

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> GAO study finds 510(k)-cleared devices account for 94% of unplanned postmarket safety studies. More

> Theranos scouts out new lab director amid testing fallout. Article

Pharma News

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. Report

> Dr. Reddy's feels FDA heat, gets warning letter for three plants. Story

> Sanofi puts 2 units on the block, commits to $1.6B in cuts to turn business around. Article

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.

Annexon Biosciences and AlloVir are seeking a $100 million IPO apiece in a buoyant market that shows no signs of slowing down.